pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Livmarli
drug · small molecule
save

maralixibat chloride

Marketedupdated 6mo ago
by $MIRM Mirum Pharmaceuticals, Inc.🔗 ChEMBL
Approved
community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 3 investigational indications.

targets

Ileal sodium/bile acid cotransporter

all catalysts(0)

nothing on the calendar yet

Trials studying maralixibat chloride

  • —Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)recruitingn=70
  • phase4Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome in the European Union (LEAP-EU)recruitingn=100

Patent cliff

source: FDA Orange Book
first barrier falls
Mar 13, 2027
116 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (42)

  • Oct 5, 2043formulationUS 12296050
  • Oct 5, 2043formulationUS 12296050
  • Oct 5, 2043formulationUS 12296050
  • Oct 5, 2043formulationUS 12296050
  • Feb 12, 2040method-of-use (U-4187)US 11229647
  • Feb 12, 2040method-of-use (U-3290)US 11229647
  • Feb 12, 2040method-of-use (U-4187)US 11229647
  • Feb 12, 2040method-of-use (U-4187)US 11229647
  • Feb 12, 2040method-of-use (U-4187)US 11229647
  • Feb 12, 2040method-of-use (U-4187)US 11497745
  • Feb 12, 2040method-of-use (U-4187)US 11497745
  • Feb 12, 2040method-of-use (U-4187)US 11497745
  • Feb 12, 2040method-of-use (U-3290)US 11497745
  • Feb 12, 2040method-of-use (U-4187)US 11497745
  • Feb 12, 2040method-of-use (U-3974)US 11918578
  • Oct 26, 2032method-of-use (U-3973)US 10512657
  • Oct 26, 2032method-of-use (U-4186)US 10512657
  • Oct 26, 2032method-of-use (U-4186)US 10512657
  • Oct 26, 2032method-of-use (U-4186)US 10512657
  • Oct 26, 2032method-of-use (U-4186)US 10512657
  • Oct 26, 2032method-of-use (U-3850)US 10512657
  • Oct 26, 2032method-of-use (U-3850)US 11229661
  • Oct 26, 2032method-of-use (U-4186)US 11229661
  • Oct 26, 2032method-of-use (U-4186)US 11229661
  • Oct 26, 2032method-of-use (U-4186)US 11229661
  • Oct 26, 2032method-of-use (U-4186)US 11229661
  • Oct 26, 2032method-of-use (U-3973)US 11229661
  • Oct 26, 2032method-of-use (U-4187)US 11376251
  • Oct 26, 2032method-of-use (U-4187)US 11376251
  • Oct 26, 2032method-of-use (U-3974)US 11376251
  • Oct 26, 2032method-of-use (U-4187)US 11376251
  • Oct 26, 2032method-of-use (U-4187)US 11376251
  • Oct 26, 2032method-of-use (U-3973)US 12350267
  • Oct 26, 2032method-of-use (U-3973)US 12350267
  • Oct 26, 2032method-of-use (U-3973)US 12350267
  • Oct 26, 2032method-of-use (U-3973)US 12350267
  • Oct 26, 2032method-of-use (U-3973)US 12350267
  • May 26, 2031method-of-use (U-4187)US 112600534.5y
  • May 26, 2031method-of-use (U-4187)US 112600534.5y
  • May 26, 2031method-of-use (U-3290)US 112600534.5y
  • May 26, 2031method-of-use (U-4187)US 112600534.5y
  • May 26, 2031method-of-use (U-4187)US 112600534.5y

FDA exclusivities (19)

  • Jul 24, 2031ODE-490Orphan Drug (7y)4.7y
  • Mar 13, 2031ODE-471Orphan Drug (7y)4.3y
  • Mar 13, 2031ODE*ODE*4.3y
  • Mar 13, 2030ODE*ODE*3.3y
  • Mar 13, 2030ODE-429Orphan Drug (7y)3.3y
  • Sep 29, 2028ODE-379Orphan Drug (7y)1.9y
  • Sep 29, 2028ODE*ODE*1.9y
  • Mar 13, 2027I-938Indication (3y)116d
  • Mar 13, 2027I-938Indication (3y)116d
  • Mar 13, 2027I-938Indication (3y)116d
  • Mar 13, 2027I-938Indication (3y)116d
  • Mar 13, 2027I-938Indication (3y)116d
  • Sep 29, 2026NCENew Chemical Entity (5y)
  • Sep 29, 2026NCENew Chemical Entity (5y)
  • Sep 29, 2026NCENew Chemical Entity (5y)
  • Sep 29, 2026NCENew Chemical Entity (5y)
  • Sep 29, 2026NCENew Chemical Entity (5y)
  • Sep 29, 2026NCENew Chemical Entity (5y)
  • Mar 13, 2026NPPNew Product (3y)

News(1)

  • Mirum succeeds in rare liver disease trial; First Tracks delivers in celiac
    Mirum Pharmaceuticals’ late-stage win in ultra-rare liver diseases: The company’s ileal bile acid transporter inhibitor Livmarli significantly reduced cholestatic pruritus versus placebo in patient…
    endpoints · 1mo ago
brand
Livmarli
trade names
Livmarli
generic
maralixibat chloride
MOA
Ileal bile acid transporter inhibitor
indication
Biliary Atresia
phase
marketed
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?